Home
HelpTest ID: HPVLR Human Papillomavirus (HPV) Low Risk, In Situ Hybridization
Shipping Instructions
Attach the green "Attention Pathology" address label (T498) to the outside of the transport container before putting into the courier mailer.
Necessary Information
A pathology/diagnostic report and a brief history are required.
Specimen Required
Supplies: Pathology Packaging Kit (T554)
Specimen Type: Tissue
Container/Tube: Immunostain Technical Only Envelope
Collection Instructions: Formalin-fixed, paraffin-embedded tissue block; or 5 unstained glass, "positively charged" slides with 4-microns, formalin-fixed, paraffin-embedded tissue
Forms
If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:
-Oncology Test Request (T729)
-Immunohistochemical (IHC)/In Situ Hybridization (ISH) Stains Request (T763)
Useful For
Detection of human papillomavirus from low-risk genotypes (6, 11)
Method Name
In Situ Hybridization (ISH)
Reporting Name
HPV Low-Risk ISHSpecimen Type
SpecialSpecimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Special | Ambient (preferred) | ||
| Refrigerated | |||
Clinical Information
Human papillomavirus infections with low-risk genotypes (6, 11) can cause benign hyperplasia, such as condylomas and papillomas.
Reference Values
Results are reported as positive or negative for types 6 and 11.
Interpretation
This test, when not accompanied by a pathology consultation request, will be answered as either positive or negative. If additional interpretation or analysis is needed, request PATHC / Pathology Consultation along with this test.
Clinical Reference
1. Lindemann ML, Dominguez MJ, de Antonio JC, et al. Analytical comparison of the cobas HPV test with hybrid capture 2 for the detection of high-risk HPV genotypes. J Mol Diagn. 2012;14(1):65-70
2. Bishop JA, Ma XJ, Wang H, et al. Detection of transcriptionally active high-risk HPV in patients with head and neck squamous cell carcinoma as visualized by a novel E6/E7 mRNA in situ hybridization method. Am J Surg Pathol. 2012;36(12):1874-1882
3. Mirghani H, Casiraghi O, Guerlain J, et al. Diagnosis of HPV driven oropharyngeal cancers: Comparing p16 based algorithms with the RNAscope HPV-test. Oral oncology. 2016;62:101-108
4. Magaki S, Hojat SA, Wei B, So A, Yong WH. An introduction to the performance of immunohistochemistry. Methods Mol Biol. 2019;1897:289-298. doi:10.1007/978-1-4939-8935-5_25
Day(s) Performed
Monday through Friday
Report Available
5 to 7 daysTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
88365-Primary
88364-If additional in situ hybridization
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| HPVLR | HPV Low-Risk ISH | In Process |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 71204 | Interpretation | 50595-8 |
| 71205 | Participated in the Interpretation | No LOINC Needed |
| 71206 | Report electronically signed by | 19139-5 |
| 71208 | Material Received | 81178-6 |
| 71595 | Disclaimer | 62364-5 |
| 72113 | Case Number | 80398-1 |
mml-gynecological-cancer, mml-head-neck-cancer